Synergy Pharmaceuticals (FRA:S90) EV-to-EBITDA : -0.58 (As of May. 17, 2024)

Synergy Pharmaceuticals EV-to-EBITDA Chart

Synergy Pharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
EV-to-EBITDA		Get a 7-Day Free Trial					-6.94	-2.98	-6.80	-7.12	-2.16

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EV-to-EBITDA	Get a 7-Day Free Trial															-2.55	-2.16	-2.17	-3.17	-3.65

Competitive Comparison of Synergy Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synergy Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's EV-to-EBITDA falls into.

Synergy Pharmaceuticals EV-to-EBITDA Calculation

Synergy Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Synergy Pharmaceuticals's current Enterprise Value is €65.50 Mil.
Synergy Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synergy Pharmaceuticals  (FRA:S90) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Synergy Pharmaceuticals's PE Ratio for today is calculated as:

Synergy Pharmaceuticals's share price for today is €0.00.
Synergy Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.480.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Synergy Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description